At CPDC we are working with our partners to discover, develop and distribute the next generation of imaging agents and targeted radiotherapeutics for the detection and treatment of human diseases.
HAMILTON, ON, June 28, 2022 /CNW/ – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, has licensed [18F]PSMA-1007 from ABX- advanced biochemical compounds GmbH (Radeberg, Germany) and will hold the exclusive license to manufacture, commercialize and distribute the imaging agent in Canada. Concurrently, CPDC is also pleased to
Radiopharmaceuticals are a special class of drugs. They’re sometimes called molecular imaging probes, contrast agents, tracers or radiotherapeutics.
Radiopharmaceuticals contain a radioactive isotope and they are used to both diagnose and treat disease. Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer.
Isotopia and CPDC shorten arrival time to patients. The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America.
CPDC is always looking for exceptional people to strengthen our team.
